Osimertinib and rociletinib have shown clinical efficacy in phase I/II trials in patients with acquired resistance to first-generation or second-generation TKIs and are currently compared to standard treatment in phase III trials in patients with advanced EGFR mutation-positive NSCLC [35, 36]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.